Pherecydes Pharma SA develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-Staphylococcus aureusphages for the treatment of bone/joint and diabetic foot ulcer infections; anti-Pseudomonas aeruginosa phages for the treatment of complicated urinary tract infections; and anti-Escherichia coli phages for the treatment of respiratory tract infections. The company was founded in 2006 and is based in Romainville, France.

ALPH

EURONEXT:ALPHE

Pherecydes Pharma Société anonyme

Last Close

2.01

23/06 15:35

Market Cap

15.83M

Beta: 0.86

Volume Today

3.15K

Avg: 7.42K

PE Ratio

−2.68

PFCF: -

locale

market

industry

website

ipo date

peer of

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics